Astrazeneca PLC balance sheet

At the end of fiscal 2025, Astrazeneca PLC had total assets of $114.07bn, total liabilities of $65.36bn and shareholders' equity of $48.67bn. It held $5.71bn in cash against $29.62bn of debt: net debt of $23.91bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Astrazeneca PLC: balance sheet, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	6.2	5.0	3.3	4.8	5.4	7.8	6.3	6.2	5.8	5.5	5.7
Receivables	6.6	4.6	5.0	5.6	5.8	7.0	9.6	10.5	12.1	13.0	15.2
Inventory	2.1	2.3	3.0	2.9	3.2	4.0	9.0	4.7	5.4	5.3	6.6
Total current assets	16.0	13.3	13.2	15.6	15.6	19.5	26.2	22.6	25.1	25.8	28.7
Goodwill	11.8	11.7	11.8	11.7	11.7	11.8	20.0	19.8	20.0	21.0	21.2
Total assets	60.1	62.5	63.4	60.7	61.4	66.7	105.4	96.5	101.1	104.0	114.1
Total current liabilities	14.9	15.3	16.4	16.3	18.1	20.3	22.6	26.3	30.5	27.9	30.6
Long-term debt	14.1	14.5	15.6	17.4	15.7	17.5	28.1	23.0	22.4	26.5	24.7
Total debt	14.1	14.5	17.8	19.1	18.2	20.4	30.8	29.2	28.6	30.3	29.6
Total liabilities	41.5	45.9	46.7	46.6	46.8	51.1	66.1	59.4	62.0	63.2	65.4
Shareholders' equity	18.5	14.9	15.0	12.5	13.1	15.6	39.3	37.0	39.1	40.8	48.7
Non-controlling interests and other (assets − liabilities − equity)	—	1.8	1.7	1.6	1.5	—	—	—	—	—	—
Net debt (negative = net cash)	7.9	9.5	14.5	14.3	12.9	12.5	24.5	23.1	22.8	24.8	23.9

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AZN vs PFE AZN vs MRK AZN vs BMY AZN vs NVO

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Astrazeneca PLC's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Astrazeneca PLC.